Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns

Journal of the National Cancer Institute

Volumn 89, Issue 20, 1997, Pages 1505-1515

  Wosikowski, Katja ^a   Schuurhuis, Danita ^a   Johnson, Kathryn ^a   Paull, Kenneth D ^a   Myers, Timothy G ^a   Weinstein, John N ^a   Bates, Susan E ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ERBSTATIN; METHOTREXATE; PACLITAXEL; PROTEIN KINASE INHIBITOR; TAXANE DERIVATIVE; THIOTEPA; TOPOTECAN; TRIAZINATE; TRIMETREXATE; URAMUSTINE; VINBLASTINE; VINCRISTINE; ZORUBICIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CYTOPATHOGENIC EFFECT; DATA BASE; DRUG EFFECT; DRUG SCREENING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; ONCOGENE C ERB; ONCOGENE NEU; PROTEIN PHOSPHORYLATION; RECEPTOR DENSITY;

EID: 0030828009     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.20.1505     Document Type: Article

References (49)

1. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-12.
2. Rajkumar T, Gullick WJ. The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 1994;29:3-9.
3. Chen WS, Lazar CS, Poenie M, Tsien RY, Gill GN, Rosenfeld MG. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 1987;328:820-3.
4. Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro Y. Accumulation of p21rasGTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc Natl Acad Sci U S A 1990;87:7926-9.
5. Frye RA. Involvement of G proteins, cytoplasmic calcium, phospholipases, phospholipid-derived second messengers, and protein kinases in signal transduction from mitogenic cell surface receptors. Cancer Treat Res 1992; 63:281-99.
6. Kyriakis JM, Force TL, Rapp UR, Bonventre JV, Avruch J. Mitogen regulation of c-Raf-1 protein kinase activity toward mitogen-activated protein kinase-kinase. J Biol Chem 1993;268:16009-19.
7. Perez R, Pascual M, Macias A, Lage A. Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat 1984;4:189-93.
8. Shoyab M, Plowman GD, McDonald VL, Bradley JG, Todaro GJ. Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 1989;243(4894 Pt 1):1074-6.
9. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RE, Tam JP, et al. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 1988;2:543-55.
10. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 1984;74:647-51.
11. Lofts FJ, Gullick WJ. c-erbB2 amplification and overexpression in human tumors. Cancer Treat Res 1992:161-79.
12. Singleton TP, Strickler JG. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol Annu 1992;27 Pt 1:165-90.
13. Harris AL. Epidermal growth factor receptor in human breast cancer. Recent Results Cancer Res 1989;113:70-7.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987;235:177-82.
15. Costa S, Stamm H, Almendral A, Ludwig H, Wyss R, Fabbro D, et al. Predictive value of EGF receptor in breast cancer [letter]. Lancet 1988;2: 1258.
16. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Fardon JR, Harris AL. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989;1: 182-5.
17. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1987;1:1398-402.
18. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66.
19. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Devel Res 1995;34:91-109.
20. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
21. Paull KD, Lin CM, Malspeis L, Hamel E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 1992;52:3892-900.
22. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994;46:627-38.
23. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 1995;95:2205-14.
24. Boyd MR, Paull KD, Rubinstein LR. Data display and analysis strategies for the NCI disease-oriented in vitro antitumor drug screen. In: Valeriote FA, Corbett T, Baker L, editors. Cytotoxic anticancer drugs: models and concepts for drug discovery and development. Boston: Kluwer Acad. Publ. 1992:11-34.
25. Stinson SF, Alley MC, Kopp WC, Fiebig H, Mullendore LM, Kenney S, et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992;12:1035-53.
26. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
27. Sambrook J, Fritsch EF, Maniatis T. Extraction, purification, and analysis of messenger RNA from eukaryotic cells. In: Nolan C, Ford N, Ferguson M, editors. Molecular cloning, a laboratory manual. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory, 1989;7.3-7.83.
28. Dickstein B, Valverius EM, Wosikowski K, Saceda M, Pearson JW, Martin MB, et al. Increased epidermal growth factor receptor in an estrogen-responsive, adriamycin-resistant MCF-7 cell line. J Cell Physiol 1993;157: 110-8.
29. Paull KD, Hamel E, Malspeis L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: Foye WO, editor. Cancer chemotherapeutic agents. Washington (DC): American Chemical Society, 1995:9-45.
30. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 1993;268:11134-42.
31. Park JW, Stagg R, Lewis GD, Carter P, Maneval D, Slamon DJ, et al. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. In: Dickson RB, Lippman ME, editors. Genes, oncogenes and hormones: advances in cellular and molecular biology of breast cancer. Boston: Kluwer Acad. Publ. 1992:193-211.
32. Sartor O, Sameshima JH, Robbins KC. Differential association of cellular proteins with family protein-tyrosine kinases. J Biol Chem 1991;266: 6462-6.
33. Fitzgerald D, Pastan I. Pseudomonas exotoxin and recombinant immunotoxins derived from it. Ann N Y Acad Sci 1993;685:740-5.
34. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-5.
35. Reiter Y, Brinkmann U, Jung SH, Lee B, Kasprzyk PG, King CR, et al. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J Biol Chem 1994;269:18327-31.
36. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW 2d, Longo DL, et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991;9: 2095-103.
37. Kihara A, Pastan I. Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor alpha. Bioconjug Chem 1994;5:532-8.
38. Dickstein BM, Wosikowski K, Bates SE. Resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 1995;110:205-11.
39. Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-44.
40. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5.
41. Onodo T, Isshiki K, Takeuchi T, Tatsuta K, Umezawa K. Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin A methyl ester in cultured A431 cells. Drugs Exp Clin Res 1990;16:249-53.
42. Umezawa K, Imoto M. Use of erbstatin as protein-tyrosine kinase inhibitor. Methods Enzymol 1991;201:379-85.
43. Uehara Y, Fukazawa H, Murakami Y, Mizuno S. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun 1989;163:803-9.
44. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-8.
45. Chabner BA. Biological basis for cancer treatment. Ann Intern Med 1993; 118:633-7.
46. Gibbs JB, Oliff A. Pharmaceutical research in molecular oncology. Cell 1994;79:193-8.
47. James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, et al. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 1993;260:1937-42.
48. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-7.
49. Fry DW, Kraker AJ, Connors RC, Elliott WL, Nelson JM, Showalter HD, et al. Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Des 1994;9:331-51.